The primary active compound in this plant is more potent than LSD.
This structural analog of DMT is an understudied compound presenting new options for psychedelic drug development.
Using psychedelics to treat chronic pain is understudied yet full of potential.
“In the pharmaceutical drug development community, this is what you dream about.”
Three doses of fluoxetine were needed to elicit the effects of one dose of noribogaine.
This collaboration will determine the full scope of the pharmacological effects of several synthetic tryptamine compounds.
This is the first preclinical study to examine the anti-depressive effects of ibogaine and noribogaine.
This technology developed by MindMed and Liechti Lab may help ease some of the concerns surrounding psychedelic therapy.
Understanding the structure of this synthetic analog of 5-MeO-DMT may help explain the effects of naturally occurring chemical cocktails.
New crystalline forms of norpsilocin create new options for developing psychedelic drug formulations.